Edition:
United States

Orexigen Therapeutics Inc (OREX.O)

OREX.O on Nasdaq

2.12USD
22 Sep 2017
Change (% chg)

$-0.17 (-7.22%)
Prev Close
$2.29
Open
$2.30
Day's High
$2.31
Day's Low
$2.01
Volume
193,680
Avg. Vol
71,449
52-wk High
$5.70
52-wk Low
$1.65

Latest Key Developments (Source: Significant Developments)

Orexigen Therapeutics Q2 loss per share $2.00
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces second quarter 2017 financial results.Q2 loss per share $2.00.Orexigen Therapeutics - qtrly revenue $23.4 million versus $7.8 million; as of June 30, co had $86.6 million in cash, & cash equivalents and marketable securities​.  Full Article

Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria
Monday, 7 Aug 2017 07:10am EDT 

Aug 7 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria.Orexigen Therapeutics Inc - ‍Cheplapharm will be responsible for all commercialization activity and expenses​.Orexigen Therapeutics Inc - ‍Orexigen will supply Mysimba to Cheplapharm for a negotiated transfer price​.Orexigen Therapeutics Inc - expect to launch Mysimba in up to eight more countries by year end​.  Full Article

Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave to Egypt
Wednesday, 26 Jul 2017 08:50am EDT 

July 26 (Reuters) - Orexigen Therapeutics Inc ::Orexigen Therapeutics announces expansion of distributorship agreement with Biologix FZCO for Contrave® (naltrexone hcl / bupropion hcl extended release) to Egypt.Orexigen Therapeutics - Orexigen also announced that regulatory applications have been submitted in Kuwait, Lebanon, Saudi Arabia and United Arab Emirates.Orexigen Therapeutics Inc - unit, Biologix FZCO amended commercialization and distributorship agreement for contrave in middle east to include Egypt.Orexigen will supply Contrave to Biologix at an agreed transfer price.Orexigen therapeutics - expects Contrave to be available for patients in Kuwait, Lebanon, Saudi Arabia and United Arab Emirates starting in q1 of 2018.Orexigen will continue to own marketing authorization for contrave.  Full Article

Orexigen Therapeutics reports Q1 loss per share $4.67
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics reports financial results for the first quarter ended March 31, 2017.Q1 loss per share $4.67.Q1 revenue $19.1 million.Orexigen Therapeutics Inc - As of March 31, 2017, Orexigen had $126.6 million in cash, restricted cash and cash equivalents and marketable securities.  Full Article

Navamedic signs deal with Orexigen Therapeutics for Nordic launch of Mysimba
Tuesday, 2 May 2017 03:00am EDT 

May 2 (Reuters) - NAVAMEDIC ASA :NAVAMEDIC ASA: ENTERS INTO PARTNERSHIP AGREEMENT WITH OREXIGEN THERAPEUTICS FOR NORDIC LAUNCH OF MYSIMBA®.HAS ENTERED INTO A FIVE-YEAR AGREEMENT WITH OREXIGEN THERAPEUTICS IRELAND, LTD., FOR NORDIC MARKETING AND DISTRIBUTION OF MYSIMBA®, A PRESCRIPTION PHARMACEUTICAL..NAVAMEDIC EXPECTS TO BEGIN MARKETING PRODUCT DURING Q4 2017 FOR AN INITIAL PERIOD OF FIVE YEARS, RENEWABLE FOR AN ADDITIONAL FIVE-YEAR PERIOD, ACCORDING TO TERMS OF AGREEMENT.  Full Article

Orexigen Therapeutics on March 28, 2017, entered into controlled equity offering sales agreement
Thursday, 30 Mar 2017 04:36pm EDT 

Orexigen Therapeutics Inc : Orexigen Therapeutics Inc- on March 28, 2017, entered into a controlled equity offering sales agreement - sec filing .Orexigen Therapeutics -under deal co may offer and sell, through agent, shares par value $0.001 per share, with aggregate offering price up to $20 million.  Full Article

Orexigen Therapeutics reports Q4 loss per share $1.69
Tuesday, 28 Mar 2017 04:21pm EDT 

Orexigen Therapeutics Inc - : Orexigen Therapeutics reports financial results for the fourth quarter and year ended December 31, 2016 . Q4 loss per share $1.69 . Q4 revenue $13.9 million versus $4.9 million .According to IMS Health, 140,755 total prescriptions of contrave were filled in q4 of 2016 versus 185,944 total prescriptions filled in q4 of 2015.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba in Italy
Monday, 27 Mar 2017 06:03pm EDT 

Orexigen Therapeutics Inc : Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy . Orexigen Therapeutics Inc- Under terms of agreement, Bruno will be responsible for all commercialization activity and expenses . Orexigen Therapeutics Inc says Bruno expects that Mysimba will be available for patients in Italy in Q4 of this year . Orexigen Therapeutics Inc - Orexigen Therapeutics Ireland, Bruno Farmaceutici executed a distributorship agreement for Mysimba in Italy .Orexigen Therapeutics-Under deal co to supply Mysimba to Bruno for negotiated transfer price, upfront milestone payments at signing, first commercial sale.  Full Article

Orexigen Therapeutics sees Q4 total revenue $13.4-$13.9 mln
Friday, 17 Feb 2017 08:57am EST 

Orexigen Therapeutics Inc : Orexigen Therapeutics Inc - Expects total revenue for q4 of 2016 to be between approximately $13.4 million to $13.9 million . Expects U.S. net sales for contrave for Q4 of 2016 to be between approximately $11.5 million to $12.0 million . Orexigen Therapeutics Inc - Company also expects U.S. net sales for contrave for q4 of 2016 to be between approximately $11.5 million to $12.0 million . Q4 revenue view $12.5 million -- Thomson Reuters I/B/E/S . Orexigen Therapeutics Inc - Expects total revenue for year ended December 31, 2016 to be between approximately $33.3 million to $33.8 million . Orexigen Therapeutics - entered into separate privately negotiated exchange agreements with certain holders of 2.75% convertible senior notes due 2020 . Q4 revenue view $12.5 million -- Thomson Reuters I/B/E/S . Fy2016 revenue view $34.0 million -- Thomson Reuters I/B/E/S .Orexigen Therapeutics - new notes bear interest at fixed rate of 2.75% per year, payable semiannually in arrears on june 1 and december 1 of each year.  Full Article

Orexigen Therapeutics announces spanish launch of Mysimba
Wednesday, 25 Jan 2017 07:40am EST 

Orexigen Therapeutics Inc : Orexigen Therapeutics announces spanish launch of Mysimba (naltrexone hcl / bupropion hcl prolonged release) in partnership with laboratorios Farmacéuticos Rovi, S.A. .Orexigen Therapeutics says laboratorios Farmacéuticos Rovi, S.A. will market Mysimba as part of portfolio under terms of distributorship agreement.  Full Article

BRIEF-Orexigen Therapeutics to provide business update

* Orexigen Therapeutics to provide business update at the 2017 Cantor Fitzgerald Global Healthcare Conference Source text for Eikon: Further company coverage: